In vivo self-assembled siRNAs targeting VEGFR2 and mTOR for renal cell carcinoma treatment - PubMed
a day ago
- #Renal cell carcinoma
- #siRNA therapy
- #VEGFR2 and mTOR
- Renal cell carcinoma (RCC) is an aggressive urologic malignancy with invasion, metastasis, and treatment resistance.
- Advanced clear cell renal cell carcinoma (ccRCC) models were established in mice via orthotopic tumor transplantation and post-surgical recurrence simulation.
- A genetic circuit was engineered to reprogram the host liver as a bioreactor for producing in vivo self-assembled siRNAs (IVSA-siRNAs) targeting VEGFR2 and mTOR.
- IVSA-siRNAs showed therapeutic efficacy in both advanced and post-surgical ccRCC models without discernible toxicity.
- The combination therapy of sunitinib and everolimus was effective but induced severe adverse effects.
- IVSA-siRNAs potently silenced VEGFR2 and mTOR expression, offering a promising multi-targeted therapy for RCC.